Onset of analgesia with ibuprofen sodium in tension-type headache: a randomized trial

Table 2 Cumulative proportion of subjects achieving relief at 0.5, 1, 2, and 3 hours

	Proportion of subjects achieving end point, %			Treatment difference (95% CI) P value ^a
	IBU _Na	IBU _Mot	Placebo	IBU _Na vs Placebo	IBU _Na vs IBU _Mot	IBU _Mot vs Placebo
30 minutes
FPR	18.7	7.9	0	18.58 (10.43–26.73) P = .002	10.91 (0.98–20.83) P = .033	7.80 (2.14–13.46) P = .055
MPR	12.1	4.5	0	12.02 (5.27–18.77) P = .015	7.62 (−0.38–15.63) P = .064	4.50 (0.13–8.88) P = .146
1 hour
FPR	76.9	74.2	15.2	62.03 (48.65–75.41) P < .001	2.96 (−9.52–15.44) P = .642	59.44 (45.69–73.19) P < .001
MPR	71.4	65.2	13.0	58.58 (44.96–72.21) P < .001	6.40 (−7.27–20.07) P = .357	52.31 (38.20–66.41) P < .001
Complete relief	0	0	0	NA	NA	NA
2 hours
FPR	85.7	86.5	45.7	40.26 (23.85–56.68) P < .001	−0.72 (−10.89–9.45) P = .889	41.19 (24.78–57.59) P < .001
MPR	85.7	86.5	39.1	46.68 (30.43–62.93) P < .001	−0.72 (−10.89–9.45) P = .889	47.59 (31.35–63.83) P < .001
Complete relief	5.5	4.5	2.2	3.21 (−3.12–9.55) P = .389	0.98 (−5.45–7.41) P = .764	2.35 (−3.69–8.39) P = .490
3 hours
FPR	85.7	86.5	45.7	40.26 (23.85–56.68) P < .001	−0.72 (−10.89–9.45) P = .889	41.19 (24.78–57.59) P < .001
MPR	85.7	86.5	45.7	40.26 (23.85–56.68) P < .001	−0.72 (−10.89–9.45) P = .889	41.19 (24.78–57.59) P < .001
Complete relief	37.4	38.2	8.7	28.71 (15.72–41.70) P < .001	−0.93 (−15.22–13.36) P = .898	29.37 (16.19–42.56) P < .001

^aTreatment difference (first treatment – second treatment) and its associated CI were calculated based on the Cochran-Mantel-Haenszel (CMH) adjusted proportions and the corresponding standard errors; P values from the CMH test, controlling for baseline Pain Severity Rating and gender. CI, confidence interval; FPR, first perceptible relief; IBU_Mot, Motrin^®; IBU_Na, ibuprofen sodium; MPR, meaningful pain relief; NA, not applicable. Statistically significant differences are indicated by bold type.

ISSN: 2055-0294